Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
January 23, 2023
Atlantic Re:think Q&A with Samer Ansari, Takeda’s Oncology Business Unit Head of Data, Digital & Technology
If you are a journalist or member of the media looking for Takeda Oncology resources, visit the media materials section of our newsroom.
For other Takeda news releases, please visit the Takeda.com Newsroom.
For media inquiries or reporter requests for more information, contact Oncology Communications via [email protected] If you generally would like to contact us, please visit Contact Us.